Topic: inflammatory diseases
Rapt Therapeutics filed to raise up to $75 million in its IPO after postponing an earlier attempt to raise $86 million in August.
The termination of the clinical trial and molecule follows slower-than-expected progress for RG6174.
The series B round comes 16 months after Viela broke free from AstraZeneca with six drugs and $250 million in funding.
Viela's inebilizumab reduced attacks from the rare autoimmune disease neuromyelitis optica spectrum disorders by 73%.
Viela Bio came to be when AstraZeneca hived off a clutch of programs in inflammatory and autoimmune diseases.
Novartis is picking up one clinical-stage and two preclinical NLRP3 antagonist programs in its acquisition of IFM Tre.
Horizon Pharma’s inflammatory eye drug teprotumumab reduced eye bulging in a phase 3 study, meeting its primary endpoint.
IFM Therapeutics is unveiling its second subsidiary, IFM Due, which will target the cGAS/STING pathway to treat inflammatory and autoimmune disease.
Inflazome has brought on Thomas Jung, M.D., Ph.D., to be its new chief medical officer and lead clinical development of its NLRP3 inhibitors.
Genentech acquired Jecure Therapeutics and its stable of NLRP3 inhibitors for an undisclosed amount.